Insilico Medicine Inc.

Insilico Medicine is a global, clinical-stage biotechnology company that leverages generative artificial intelligence (AI) to accelerate drug discovery and development. Founded in 2014, its mission is to extend healthy, productive longevity by transforming the pharmaceutical industry through AI, significantly reducing the time and cost associated with bringing life-saving medications to patients. The company's primary headquarters are located in Cambridge, Massachusetts, with a significant global presence including facilities in Hong Kong, New York, Montreal, Suzhou, Abu Dhabi, Shanghai, and Taipei.

At the core of Insilico Medicine's operations is its proprietary end-to-end Pharma.AI platform, which integrates biology, chemistry, and clinical development. This platform comprises key components such as PandaOmics for novel target discovery, Chemistry42 for generative molecular design, and InClinico for clinical trial prediction and optimization. The company focuses on developing novel therapeutics for a range of diseases, including cancer, fibrosis, immune disorders, central nervous system conditions, infectious diseases, autoimmune diseases, and age-related conditions.

Insilico Medicine became publicly traded on the Hong Kong Stock Exchange (HKEX: 3696) following its IPO on December 30, 2025. The company has achieved notable milestones, including advancing the first generative AI-discovered and AI-designed drug, Rentosertib (ISM001-055), into Phase II clinical trials for idiopathic pulmonary fibrosis. Recent significant developments include a landmark $2.75 billion collaboration with Eli Lilly in March 2026 and a record-breaking $2.5 billion global R&D partnership with SK Biopharmaceuticals in June 2026. The company is led by founder, co-CEO, and Chief Business Officer Alex Zhavoronkov, PhD, and co-CEO and Chief Scientific Officer Feng Ren, PhD.